BSIM is a biotech company focused on the design of organ-targeted, high-quality drug candidates for the treatment of transthyretin-mediated amyloidoses.
Coimbra, Portugal
Joined September 2019
- Tweets70
- Following465
- Followers315
- Likes72
Pinned Tweet
We’re pleased to announce the selection of our first drug candidate, BSIM 3A05D, a compound designed to address #ATTR-CM, a progressive and potentially fatal disease characterized by deposition of TTR amyloid in the heart.
Full PR: bsimtx.com/news/28
#amyloidosis
More than 300 M people worldwide live with a rare disease.
Today BSIM joins #RareDiseaseDay observance and reaffirms its commitment towards improving the quality of life of patients with #hATTR, a group of rare and severe conditions.
BSIM has been awarded two IP vouchers from the “@IdeasPowered for business #SMEFund”, a grant scheme designed by the @EU_IPO to help EU #SMEs protect their IP rights. We acknowledge this financial support and will use it to uphold our strong commitment to #IPprotection.
At the close of another year, BSIM Therapeutics wishes you a joyous Holiday Season and a New Year filled with peace and happiness.
Preclinical data obtained with the small molecule BSIM-3A05D show the compound effectively stabilizes transthyretin (TTR) and prevents #amyloid formation by different TTR variants with unprecedented efficacy.
#cardiomyopathy #amyloidosis #ATTR-CM
BSIM Therapeutics has recently announced the selection of its first drug candidate – small molecule BSIM-3A05D – designed to prevent or treat hereditary and wild type transthyretin #amyloidosis with #cardiomyopathy presentation (#ATTR-CM).
BSIM Therapeutics retweeted
Segundo o SIC Notícias,empresa de biotecnologia anunciou a seleção de um medicamento para tratar a Amiloidose Cardíaca..
Leia: sicnoticias.pt/saude-e-bem-e… .
BSIM Therapeutics retweeted
Empresa de Coimbra desenvolve medicamento experimental para doença rara que afeta o coração sicnoticias.pt/saude-e-bem-e…
BSIM Therapeutics retweeted
Empresa de Coimbra desenvolve medicamento experimental para doença rara no coração dlvr.it/SCl7rm
BSIM Therapeutics retweeted
A BSIM Therapeutics anuncia a seleção de Composto Candidato para o tratamento da Cardiomiopatia Amilóide associada a Transtirretina (ATTR-CM), uma potencial nova arma terapêutica contra um inimigo silencioso.
Mais informações em bsimtx.com
Today, BSIM is sharing drug R&D work and experience with other companies and research labs at INOVAÇÃO@UC, an event to promote networking and collaboration among researchers at the University of Coimbra, tech companies, and other R&D institutions.
More at inova.uc.pt/
For the second time around, BSIM has been awarded a US patent (# 11,117,877) for a novel technology for the treatment of #ATTR.
This is a step forward in the consolidation of a strong IP portfolio and in our efforts to answer to unmet medical needs of ATTR patients.
#amyloidosis
#Amyloid diseases are wide ranging, progressive and most times fatal. Early and accurate diagnosis is central to patient care.
BSIM supports @AmyloidosisA effort in raising awareness of amyloid diseases in this first #WorldAmyloidosisDay. Check the program worldamyloidosisday.org
(2.)
In this #WorldHeartDay BSIM joins the World in raising awareness for cardiac diseases and reaffirms its commitment to work for therapeutic solutions in the treatment of TTR-related amyloidosis with cardiac involvement (#ATTR-CM).
#CardiacAmyloidosis #ATTRCM
(1.)
Did you know that cardiac involvement in TTR-related amyloidosis (#ATTR-CM) is associated with heart failure with preserved ejection fraction and has an incidence of approx. 3 cases per 10.000 in the European Union?
#WorldHeartDay #CardiacAmyloidosis
link.springer.com/article/10…
BSIM keeps on striving to develop innovative therapeutic solutions endowed with the pharmacodynamics and pharmacokinetics properties to address the unmet medical needs in ATTR (3/3).
#ATTR #hATTR #Amyloidosis #amyloidosisawareness #BSIMTherapeutics #BSIMtx
Moreover, the increasing clinical importance of cardiac manifestations of #ATTR and the efforts being made to address them through diagnostic tools and therapeutic approaches have been extensively pointed out by several speakers (2/3).
#CardiacAmyloidosis #ATTRCM
Earlier this month, BSIM attended the “3rd European ATTR Amyloidosis meeting for Patients and Doctors”. The increasing incidence and impact of CNS impairment in #ATTR have received new attention, emphasizing the urgent need of more tailored and organ-targeted therapeutics (1/3).
At BSIM Therapeutics we strive to discover and develop innovative therapeutic solutions with one goal in mind: to improve the quality of life of patients suffering from transthyretin amyloidosis with polyneuropathy and cardiomyopathy (#ATTR #hATTR #ATTRCM #CardiacAmyloidosis).
Following the registration in Europe China and Japan, BSIM Therapeutics now sees its trademark registered in the USA. We reaffirm our commitment to see our name associated with the best therapeutic options for #ATTR.
#trademark #USPTO #amyloidosis
